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The control of human health and diseases in the elderly population is becoming a challenge, since mean age and
life expectation are progressively increasing as well as chronic degenerative diseases. These disorders are of
complex diagnosis and they are difficult to be treated, but it is hoped that the predictive medicine will lead to
more specific and effective treatment by using specific markers to identify persons with high risk of developing
disease, before the clinical manifestation. Peripheral blood targets and biomarkers are currently the most practical,
non-invasive means of disease diagnosing, predicting prognosis and therapeutic response. Human longevity is
directly correlated with the optimal functioning of the immune system. Recent findings indicate that the sexual
dimorphism of T helper (Th) cytokine pathways and the regulation of Th cell network homeostasis are normally
present in the immune response and undergoes to adverse changes with ageing. Furthermore, immune
senescence affects both men and women, but it does not affect them equally. Therefore, we hypothesize that the
comprehension of the interferences between these gender specific pathways, the ageing immunological
mechanism in pathological or healthy state and the current therapies, could lead to specifically tailored treatment
and eventually improve the therapeutic success rates. Reaching this aim requires the identification of ageing
gender-specific biomarkers that could easily reveal the above mentioned correlations.Background
The progressive increase of mean age and life expect-
ation are correlated to a rise of chronic degenerative dis-
eases such as cancer, cardiovascular, autoimmune or
neurodegenerative diseases among the elderly population
and these changes will challenge our ability to manage
human health and diseases of this category. To this aim,
researchers are conducting programs to better under-
stand human ageing and ageing-related diseases and* Correspondence: annamaria.berghella@cnr.it
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reproduction in any medium, provided the ordysfunction. Chronic degenerative diseases are of com-
plex diagnosis, they are difficult to be treated and they
absorb an increasing proportion in the health care bud-
gets worldwide, a phenomenon that will bring social,
political, economic and biomedical challenges to future
generations [1]. However, recent developments in mod-
ern medicine, especially in genetics, proteomics, and in-
formatics, are leading to the discovery of biomarkers
that can be used as indicator of disease’s risk in healthy
subjects.
Predictive medicine uses markers to identify persons
with high risk of developing disease before the clinical
manifestation. It is hoped that this approach will lead to
more specific and effective treatment in the not tooal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Berghella et al. Immunity & Ageing 2012, 9:24 Page 2 of 12
http://www.immunityageing.com/content/9/1/24distant future but this success depends upon the identifi-
cation of specific biomarkers that can be measured easily
and early, from disease onset. Peripheral blood targets
and biomarkers are currently the most practical, non-
invasive means of disease diagnosing, predicting progno-
sis and therapeutic response [2].
The identification of ageing gender-specific pathways
and biomarkers in peripheral blood would therefore
open up an interesting field for research in human
health and disease, since gender is related to disease sus-
ceptibility [3] and these pathways suffer adverse changes
with ageing. Researchers have been shown that sex ster-
oids, for example, influence the regulation of Th cell
network balance, shifting the balance toward a Th1 and/
or Th2 type response and both clinical and experimental
data have demonstrated the presence of a natural sexual
dimorphism in the immune response [3-6]. During their
reproductive years, females have a more vigorous cellu-
lar and humoral immune response than males and they
also have a greater ability to reject tumors and homo-
grafts [7-12]. Furthermore, immunosenescence affects
both men and women, but it does not affect them
equally. Men (all ages) and postmenopausal women ex-
hibit diminished T cell immunity compared to premeno-
pausal women [13]. The decrease in androgens in men
with ageing may contribute to their immunosenescence;
however, the loss of T cell function in men with ageing
is significantly less dramatic than what has been
observed in women [14-16]. There are multiple forms of
estrogen: estrone (E1), estradiol (E2) and estriol (E3) are
the primary circulating forms. Estradiol binds both es-
trogen receptor-(ER)α and ERβ with high and equal af-
finities, while estrone preferentially binds ERα at a 5-fold
higher affinity than ERβ [17]. However, both pathways
are involved in mediating estrogen effects, but ERα and
ERβ exhibit distinct functions within immune cells [18].
In premenopausal women ovary-derived estradiol is the
principal circulating estrogen, while estrone is the most
abundant circulating estrogen in postmenopausal women
and men. In men, testosterone is the primary substrate for
estrogen production by peripheral aromatization of andro-
gens precursors, but exhibits a small age-related decrease.
Furthermore, most studies failed to observe any significant
influence of age on total E2 levels in men [16].
Presentation of the hypothesis
Therefore, the comprehension of how and why immune
responsiveness changes in humans with ageing is essen-
tial for developing strategies to prevent or restore
deregulated immunity and assure healthy longevity.
Here, we advance the hypothesis that the discover of
how gender influences age immunological mechanisms
in health and disease, and the identification of ageing
gender-specific biomarkers, could lead to specificallytailored treatment and ultimately improve therapeutic
success rates. We discuss published data on gender-
dependent immune responses in health and disease
states.
It is well established that the gender of a host can sig-
nificantly affect susceptibility to infection [19]. Epi-
demiological clinical data and animal models of various
human illnesses including sepsis [20] and listeriosis
[21,22] reveal that males and females handle infections
differently and gender-dependent immune pathways or
molecules cause different disease susceptibility in men
and women (Table 1).
Women have a more powerful immune system than
men: the production of estrogen by females could have a
beneficial effect on the innate inflammatory response
against bacterial pathogens. Inflammatory caspases, for ex-
ample, are important effectors of innate immunity [23] and
the activity of caspase-1 is regulated by related inflamma-
tory caspases, namely caspases-5 and -11, which activate
select inflammasomes [24,25], and caspase-12, which
represses caspase-1 catalysis [26]. Caspase-12 is expressed
in all mammals tested to date, but has acquired deleterious
mutation in humans [26]. A single-nucleotide polymorph-
ism introduces a premature stop codon in caspase-12 in
the majority of the population. In a study, a fully huma-
nized mouse that expresses the human caspase-12 rare
variant (Csp-12 L) in a mouse casp-12-/- background, was
generated and the modalities by which human caspase-12
confers susceptibility to infection [27] was examined. In
this study, an unsuspected hormonal regulatory mechan-
ism that governs human Csp-12 L expression during infec-
tion, has been identified. These results indicate that
through estrogen production, females have a built-in
mechanism that prevents Csp-12 L from being expressed,
favoring more robust inflammatory and immune responses
to pathogens [27].
Sex steroids influence the regulation of Th cell net-
work balance, shifting the balance toward a Th1 and/or
Th2 type response. In healthy men and women, the
polarization of immune response into Th1 or Th2 cyto-
kines or cellular types is not absolute and the ratio of
these cells varies according to physiological demand and
clinical conditions [28]. In vivo and in vitro studies in
mice have demonstrated that cytokines play a crucial
role in maintaining balance in the differentiation of T
cells into Th1 or Th2 types [29]. It was found that
pathological conditions arise from abnormalities in the
balance between the production of Th1 and Th2 cyto-
kines [30]. It seems that the relative proportion of each
cell type depends on the environmental cytokines
present during activation [31].
The sex hormones may affect the Th1/Th2 balance, in
men and women. However, if we consider the susceptibility
difference to autoimmune diseases and infectious diseases
Table 1 Gender-dependent immune pathways or molecules that causes different disease susceptibility in men and
women
Gender dependent immune pathways or molecules Disease susceptibility References
Caspase-12 long variant infectious diseases Yeretssian G, Proc Natl Acad Sci, 2009, 106:9016
Glucocorticoid receptor pathways infectious diseases Wynne O, Stress, 2011, 14:247
Sulfur-dependent detoxification pathways autism Al-Yafee YA, BMC Neurol, 2011, 11:139
MyD88-dependent pathway type 1 diabetes Sheng H J, Immunol, 2011, 187:1591
STAT5-dependent pathway human growth disorders Davey HW, Am J Hum Genet, 1999, 65:959
Toll-like receptor 4 chronic pain Sorge RE, J Neurosci, 2011, 31:15450
B7-H1-dependent pathway melanoma Lin PY, J Immunol, 2010, 185:2747
PARP-1-dependent pathway lupus nephritis Caricchio R, NIH RePORTER, 2012, 08 01
HLA-DRB1*0401 and HLA-DQ8 arthritis Behrens M, J Autoimmun, 2011, 37:95
Rac1, NOX, ROS kaposi's sarcoma Goldschmidt CPJ, NIH RePORTER, 2010, 05 01
CTLA4 hepatitis C Schott E, J Hepatol. 2007, 46:372
Toll-like receptor 7 chronic HCV-infection Schott E, J Hepatol, 2007, 47:203
Aim2 and p202 proteins systemic lupus erythematosus Panchanathan R, Mol Immunol, 2011, 49:273
Retinoid x receptor alpha hepatocellular carcinogenesis Guo M, BMC Genomics, 2008, 9:403
MAPK signaling systemic lupus erythematosus Xie H, Arthritis Rheum; 2011, 63:2425
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kines could be the result of the adaptive response, rather
than the cause of the different susceptibility. This implies
that hormone-dependent mechanisms operate in the selec-
tion of cell phenotypes that regulate the adaptive response
and which, if altered, may affect the balance of the Th cells.
Induction of Treg cells by estrogen physiological level was,
for example found [32]. These authors conclude that estro-
gen is a potential physiological regulatory factor for the per-
ipheral development of CD4+CD25+Treg cells [32]:
estrogen receptor exist on the CD4+CD25- T cells and the
conversion of CD4+CD25- T cells into CD4+CD25+ Treg
cells is stimulated by estrogen. Additionally, it was discov-
ered that hormones peripherally activated pro-hormones
and regulated the Th1/Th2 balance [33].
There is evidence that sex hormones can affect the im-
mune system and that female and male hormones act in
opposing ways [34,35]. For example, Th1 and Th2
responses appear affected by androgenic and estrogenic
preponderance, respectively: androgens favor the devel-
opment of a Th1 response and activation of CD8 cells
[36], while estrogens seem to direct the immune system
towards Th2 dominance, where B lymphocytes are acti-
vated and antibody production flourishes [35]. Preg-
nancy, a high estrogen state, is of course characterized
by Th2 preponderance, and a failure in the establish-
ment of the Th2 dominance has been associated with
increased risk for pregnancy loss [37,38].
Gender accounts for important differences in the inci-
dence and prevalence of a variety of age-related diseases.
Research finding [39-41] points out that gender is amajor variable in the genetics of longevity, suggesting
that men and women follow different strategies to reach
longevity. These results [41] confirm the age-related re-
modelling of cytokine network and that variations in
pro- or anti-inflammatory cytokines might influence suc-
cessful ageing and longevity, suggesting that the multi-
plex analysis of cytokine levels might be useful in
defining a successful ageing profile [41,42].
A recent study [43] focusing on gender-dependent
immune responses indicates, for the first time, that
gender-specific Th cytokine pathways may well be re-
sponsible for the different gender-dependent responses
to disease and therapy and open up an exciting new
field for research. This study supports the concept that
a sexual dimorphism of Th cytokine pathways and regu-
lation of Th cell network homeostasis are normally
present in the immune response. Antigen presenting
cells (APCs) regulate Th cell differentiation and Th cell
network homeostasis under resting and activated condi-
tions of the immune system in both men and women,
however this effect appears to be exerted through male
and female gender-specific and gender-common health
pathways (Figure 1).
IFNγ and IL6 production pathways are the respect-
ively male and female gender-specific health pathways
for the immune response homeostasis and they are tar-
gets and/or biomarkers for the passage from health to
adenoma and, eventually, to colorectal cancer. IL10
pathway is the common-gender pathway which restores
immune system resting homeostasis in both men and
women, but only if it is controlled by the above
Figure 1 Cytokine regulation of immune response cell phases through gender specific pathways. Antigen presenting cells (APCs) regulate
Th cell differentiation and Th cell network homeostasis under resting and activated conditions of the immune system in both men and women,
however this effect appears to be exerted through male and female gender-specific health pathways: IL6 pathways regulate the homeostasis of
the Th cell network in women, whilst this homeostasis is regulated by IFNγ pathways in men. The study [28] indicates that these regulatory
differences do not usually have consequences until IFNγ and/or IL6 cytokine pathway alterations occur, ensuring the same result: a physiological
homeostasis between Treg, Th17 and Th9 cells in the resting state, in the transition to the activation phase and in the return to the resting state.
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pathway is a target/biomarker for cancer progression.
These findings showed that: i) the immune cell produc-
tion of IL6 in women and IFNγ in men decreases with the
increasing of the age (Figure 2); ii) age could also be a sig-
nificant independent factor for IFNγ and IL10 in men; iii)
whilst in women age appears to be significant for IFNγ
and the soluble interleukin 6 receptor (sIL6R) molecule,
which forms a ligand–receptor complex with IL6, that is
capable of stimulating a variety of cellular responses
including proliferation, differentiation and activation of
inflammatory processes [44].
Figure 2 shows that IFNγ level decreases with aging in
healthy men, however the IL2 level seems to be a better
candidate than IFNγ level. To verify the IFNγ role as a gen-
der-specific pathway, the authors use their mathematical
modeling by excluding IL2 and IFNy cytokines alternately.
The graphs obtained from the principal component analysis
(Figure 3), clearly define the homeostatic role of IFNy and
the IFNy-dependence of IL2. Indeed, excluding IL2 the
relationships of the cytokine network are not affected, how-
ever the exclusion of IFNy completely reshapes these
relationships.
Gender specific variations in cytokine network relation-
ships between pro- or anti-inflammatory cytokines influ-
ence the success of the immune response [41]. The results
of the above mentioned study [43] showed that the earlyevolution of immune response is influenced by the posi-
tive inter-regulation between production of IFNγ-IL10
and IL6-IL4 cytokines in men, and the negative inter-
regulation of IL6-IL10 cytokines in women. Similarly, the
late evolution of immune response seems to be influenced
by the positive inter-regulation between the production of
IFNγ-IL4 in men and by IL6-IFNγ in women. These
gender specific cytokine network relationships, between
pro- or anti-inflammatory cytokines, vary with the in-
creasing of the age (Figure 4) and they are dual gender
specific biomarkers that could well be used to develop
more specific approaches.
Overall, these findings underline the need for gender
specific drugs that could take into account the different
regulation system of the immune response, ensuring the
same therapeutic result: the return to a physiological
homeostasis thanks to the transition from a pathological
activation phase to a physiological resting state. Obvi-
ously the regulatory differences do not usually have con-
sequences until IFNγ and/or IL6 cytokine pathway
alterations occur, in which case the consequences for
men and women, in terms of pathological mechanisms
and disease development, are different. The malfunc-
tioning of gender specific pathways not only compro-
mises the homeostasis of the immune response, but may
also cause a pathological polarization of T cell subsets
specific to each sex. In fact, IFNγ supports the
Figure 2 The serum levels of IL6 in women and IFNγ in men
decrease with increasing age. A group of 66 healthy subjects of
Italian people, 33 men and 33 women (blood donors, laboratory
staff and relative), were studied [28]. None of the subjects was
receiving concurrent drug treatment including widely-used
pharmaceuticals, such as salicylates and sex hormones
(contraceptive pill, hormone replacement therapy). Distribution of
age in male and female groups was the same (mean ± SD =
41 ± 12 years, compared to mean ± SD = 41 ± 15 years, p = 0.14).
In physiological systems components operate as a network and
each component varies and co-varies dynamically with respect to
one another. Therefore, the identification of physiological pathways,
and correlated biomarkers can only be achieved through evaluations
that take these fluctuations into account. Using the principal
component analysis these authors plotted the network of vectors
obtained by analyzing the data matrix of correlation/covariance
coefficients of serum cytokines. In these plots, the angle between
vectors is inversely proportional to the degree of correlation
between vectors; the same vector direction indicates a positive
correlation/covariance, the opposite vector direction indicates a
negative correlation/covariance. This allows a visualization of the
situation under study and is an excellent method for capturing
significance from systems biology evaluations. The plots show that
the serum levels of IL6 in women and IFNγ in men decrease with
increasing age. The results of multiple regression analysis confirm
that age could also be a significant independent factor for IFNγ
(p = 0.01) and IL10 (p = 0.03) in men; whilst in women age appears
to be significant for sIL6R (p = 0.002) and IFNγ (p = 0.04).
Berghella et al. Immunity & Ageing 2012, 9:24 Page 5 of 12
http://www.immunityageing.com/content/9/1/24development of Th1 functions [45] promoting cell
mediated immunity, while IL6 cytokine supports Th2
responses where B lymphocytes are activated and anti-
body production flourishes. Additionally, research in this
field has shown that it is not a single cytokine that deter-
mines a particular response but rather the interaction of
individual cytokines within a network.
The results of the above mentioned study [43] indicate
that a different gender susceptibility and clinical course
in diseases is caused by different Treg, Th17 and Th9
cell polarization (Figure 5) determined by the TGFβ, IL6,
IFNγ, IL10 and IL4 cytokine pathway interactions which
vary between men and women [43]. These findings are,
indeed, backed up by the results of other researches in-
dicating that there is a reciprocal development relation-
ship between Treg, Th17 and Th9 cells because: i) TGFβ
triggers the expression of Foxp3 transcription factor in
naïve T cells, generating Treg cells, but ii) IL6 inhibits
the TGFβ driven expression of Foxp3, and TGFβ to-
gether with IL6 induce ROR-gt transcription factor, trig-
gering the developmental program of Th17 cells [46],
while ii) IL4 also inhibits TGFβ induction of Foxp3 ex-
pression, but TGFβ together with IL4 induce the differ-
entiation of Th9 cells, which produce IL9 cytokine. On
the other hand, the co-expression of IL9 and IL17 was
identified as a novel Th17 function in mediating im-
mune and autoimmune tissue destruction [47,48], also
in the central nervous system. Hence, autoimmune dis-
ease susceptibility in women, such as multiple sclerosis
(MS), could be attributed to the influence of ΙL6, which
plays a key role in autoimmune diseases, since it is a T
cell differentiation switch factor from Tregs to Th17
cells [46,49-51]. The greater likelihood of men develop-
ing the primary progressive MS form [52], on the other
hand, could be the result of the influence of IFNγ on
Th9 cell inhibition. In fact, the IL9 receptor complex is
constitutively expressed on astrocytes. IL9 induces astro-
cytes to produce CCL-20 but not other chemokines, in-
cluding CCL-2, CCL-3, and CXCL-2 [53], suggesting
that IL9 induces CCL-20 production by astrocytes to in-
duce the migration of Th17 cells into the CNS. Treg,
Th9 and Th17 cells have been shown to be important
CD4 T cell subsets in human autoimmune diseases, in-
cluding rheumatoid arthritis [54] and MS [55] diseases.
Our recent research on MS disease (article in press)
confirms these data, by showing that a sexual dimorph-
ism in autoimmune diseases is the result of different
pathways that regulate the Th cell network homeostasis:
IL6 pathways in women and IFNγ pathways in men.
Since women are more susceptible to MS disease and
the IL6 has a more significant role in the autoimmune
process compared to IFNγ, it is logical to assume that IL6
pathways are in some way implicated in the prevalence of
autoimmune diseases in women. Indeed, our data indicate
Figure 3 Homeostatic role of IFNy pathway and IFNy-dependence of IL2 pathway in heathy men. In the APC analysis, in heathy men
(Figure 2) IFNγ level decreases with aging, however the IL2 level seems to be a better candidate than IFNγ. The authors use their mathematical
modeling to verify the IFNγ role as a gender-specific pathway, by excluding from the model IL2 and IFNy alternately. The graphs obtained from
this analysis, clearly define the homeostatic role of IFNy and IFNy-dependence of IL2. Indeed, excluding IL2 reports from the network of cytokines
are not affected, however the exclusion of IFNy completely reshapes these relationships.
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and an increase in neurological deficit in both men
and women groups of MS patients, underlining the auto-
immune etiology of MS disease. In further support
of differing cytokine pathways in men and women, we
noted that the efficacy of IFNβ-treatment in the re-
establishment of Th-network balance and delaying the
progression of neurological disability is linked to the IL6
pathway in women, but to the IFNγ pathway in men.
The specific mechanisms responsible for gender spe-
cific disease susceptibility have yet to be clarified. How-
ever these data suggest that the answer may lie in the
different capacity of cells to defend themselves against
oxidative stress [56]. The cells of men and women differgreatly in terms of reactive oxygen species (ROS) pro-
duction and oxidative stress susceptibility [57] and this
appears to be a promising new field of investigation.
Oxygen metabolism can lead to the production of ROS in
all cell types. All cell types, including lymphocytes and
other immune system cells, present antioxidant com-
pounds and enzymes (such as glutathione and thioredoxin
reductase) [58,59] to neutralize ROS and to preserve the
cell oxidative balance. However, the activities of ROS ap-
pear to be regulated differently in males and females and
can be directly influenced by sex hormones [57].
In vivo studies have further demonstrated the incap-
acity in males, but not in females, of maintaining intra-
cellular reduced redox conditions, essential for normal
Figure 4 Gender specific ageing variations in cytokine network relationships between pro- or anti-inflammatory cytokines could
influence the success of the immune response. The study results indicate that variations in specific cytokine network relationships, between
pro- or anti-inflammatory cytokines, regulate immune response homeostasis in healthy state. The early evolution of immune response is
controlled by the positive inter-regulation between production of IFNγ-IL10 and IL6-IL4 cytokines in men, and the negative inter-regulation of
IL6-IL10 cytokines in women. Similarly, the late evolution of immune response seems to be regulated by the positive inter-regulation between
the production of IFNγ-IL4 in men and by IL6-IFNγ in women. The principal component analysis has shown that these gender specific cytokine
network relationships suffering changes during ageing, which could adversely affect the success of the immune response. Consequently, these
cytokine relationships are dual gender specific biomarkers that could well be used to develop more specific approaches in the elderly population.
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Figure 5 A different gender susceptibility and clinical course in diseases during ageing could be caused by different Treg, Th17 and
Th9 cell polarization. IFNγ and IL6 cytokine pathway alterations occur with ageing, and the consequences for men and women, in terms of
pathological mechanisms and disease development, are different because the malfunctioning of gender specific pathways not only compromises
the homeostasis of the immune response, but may also cause a pathological polarization of T cell subsets specific to each sex. The results of the
above mentioned study [28] indicate that a different gender susceptibility and clinical course in diseases during ageing is caused by different
Treg, Th17 and Th9 cell polarization determined by the IFNγ and/or IL6 gender cytokine pathway interactions, which vary between men and
women and with ageing [28]. Hence, autoimmune disease susceptibility in women could be attributed to the influence of ΙL6 which plays a key
role in autoimmune diseases, such as multiple sclerosis, since it is a T cell differentiation switch factor from Tregs to Th17 cells. The greater
likelihood of men developing the primary progressive multiple sclerosis form, on the other hand, could be the results of the influence of IFNγ on
Th9 cell inhibition.
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the differences between the two sexes in the mainten-
ance of the immune system homeostasis. In fact, IFNγ
is a direct stimulator of the gene expression of thiore-
doxin and thioredoxin reductase (RTrx) system in
human T cells [59,60] and there is a positive feed-back
circuit involving IFNγ and Trx/RTrx gene expression in
the regulation of intracellular reduced oxidative condi-
tion, which is essential for the immune response. Subse-
quently, we can assume that the immunological
response through the IFNγ pathway in men reduces the
intracellular oxidative levels to preserve the cell oxida-
tive balance control. In fact, male cells, as we men-
tioned, are incapable of maintaining an intracellular
reduced oxidative condition.
Implications of the hypothesis
The comprehension of how and why immune respon-
siveness changes in humans as they age is essential for
developing strategies to prevent or restore deregulated
immunity and assure healthy longevity. Research find-
ings showed that:1. gender is a major variable in the genetics of longevity
and men and women follow different strategies to
reach longevity [39-41];
2. gender-specific Th cytokine pathways and the
regulation of Th cell network homeostasis are
normally present in the immune response
[43]; IFΝγ and IL6 production pathways are
the respectively male and female gender-specific
health pathways for immune response
homeostasis; IL10 pathway is the common-gender
pathway which restores immune system
resting homeostasis in both men and women, but
only if it is controlled by the above mentioned
gender specific pathways; these regulatory
differences do not usually have consequences until
IFΝγ and/or IL6 cytokine pathway alterations
occur and IL6 and IFNγ pathway suffer
adverse changes with ageing
[43,61];
3. the cytokine network undergoes age-related
remodelling [41], variations in pro- or
anti-inflammatory cytokines might influence
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analysis of cytokine levels are useful in defining a
successful ageing profile [41,42];
4. the early evolution of immune response is influenced
by the positive inter-regulation between production
of IFNγ-IL10 and IL6-IL4 cytokines in men, and the
negative inter-regulation of IL6-IL10 cytokines in
women [43]. Similarly, the late evolution of immune
response seems to be influenced by the positive
inter-regulation between the production of IFNγ-IL4
in men and by IL6-IFNγ in women. These cytokine
relationships are “dual gender specific biomarkers”
that could well be used to develop more specific
approaches.
These independent findings support a new perspective
of research: the comprehension of how the different
gender pathways interfere with ageing and lead to
diseases, and how they interfere with the success of
current therapies, is of utmost importance in transla-
tional medicine physiological treatment. The above
mentioned gender-specific Th cytokine pathways and
the “dual gender specific cytokines” are peripheral blood
ageing gender-specific targets and biomarkers and
would open up an interesting field for research in
human health and disease.
Indeed, important points support the validity of our
hypothesis and feasibility of this new research perspec-
tive, looking for ageing gender specific biomarkers that
can be identified from the general ageing population.
One of the biggest problems in finding good biomar-
kers of ageing is that so many measures are indicators of
disease rather than measures of "normal" function [62].
Some gerontologists believe that ageing is not a process
or set of processes, but rather is the cumulative effect of
damage that makes the body unable to response to ex-
ternal stimuli, others believe that ageing is itself a dis-
ease. Searching for biomarkers of ageing only makes
sense if there really are relevant biological processes to
be measured [62].
The process of ageing is a complex phenomenon, it is
the consequence of the deterioration of more than one
system [62,63]. Ageing, in the biological sense, is the loss
of the ability to maintain homeostasis, that means the
loss of the ability to respond to environmental chal-
lenges, such as heat or cold or infection, by a) overcom-
ing the challenge and b) restoring normal function. Loss
of homeostatic ability can occur at the level of the whole
organism or in one or more of its parts.
This assumption leads to the conviction that a “panel”
of biomarkers that reflects the condition of an array of
critical systems is needed in order to assess the biological
age of any organism. Therefore, a specific “panel” could be
useful if the biomarkers are predictive of the deteriorationin multiple systems. A “panel” of such biomarkers would
allow predictions of health span that might be quite differ-
ent from lifespan.
A low-grade systemic inflammation characterizes ageing
and this pro-inflammatory status underlies biological
mechanisms responsible for age-related inflammatory dis-
eases [64]. On the other hand, clinical and epidemiological
studies show a strong association between chronic infec-
tion, inflammation and age-related disease. A wide range of
factors, including smoking, infections, obesity, genetics and
declining of sex hormone levels may contribute to systemic
low-grade inflammatory activity in older individuals [65].
Progressive increase of mean age and life expectancy paral-
lels, in fact, an increment of chronic inflammation which
are an index of risk for chronic degenerative diseases such
as cancer, cardiovascular, autoimmune or neurodegenera-
tive diseases among the elderly. The goal must be to iden-
tify non-symptomatic individuals with high susceptibility to
the disease, which can benefit from protocols for the pre-
vention or early intervention.
Therefore, predictive medicine must 1) as a first step
anticipate the deleterious effect of chronic degenerative
diseases using markers to identify people with chronic-
inflammatory status and 2) then use high risk markers
to predict the developing of a specific chronic degenera-
tive disease before the clinical manifestation. This in-
novative approach may offer substantial advantages,
since the promise of personalized medicine is to pre-
serve individual health in people with high risk by start-
ing early treatment or prevention protocols [1].
On the basis of the above considerations a feasible
plan, predictive and diagnostic for physiological ageing
and age linked diseases, can be identified by using as
first step a) the immunological “panel” of “dual gender
biomarkers” and then b) the high risk markers for devel-
oping a specific chronic degenerative disease, generated
by molecular, genetic and neuroimaging techniques.
The use of the immunological “panel” of “dual gender
biomarkers” as first approach to identify people with
pro-inflammatory status is supported by the following
reasons:
1. The levels of “dual gender-specific cytokines” are
dual-biomarkers of gender-specific Th cytokine
pathways. They are measurable “non-disease related
aging biomarkers”, useful to indicate if the subject
conditions comply with an healthy state or with a
transition to a chronic-inflammatory state. These
biomarkers select the population according to gender
that, as we reported, is the main biomarker for
biological and functional differences in the immune
response, susceptibility to disease and therapeutic
response. “Dual gender biomarkers” represent gender
specific biomarkers for homeostasis in the immune
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correlated with the optimal functioning of the
immune system.
2. The gender-specific Th cytokine pathways are
gender-specific target underlying healthy biological
processes, that can be related to relevant functions
and to be measured in healthy people.
3. Cytokines are easily measurable biomarkers, as they
reside in peripheral blood .
4. These immunological biomarkers are predictive of
the deterioration in multiple systems that would
allow predictions of health span that might be quite
different from lifespan.
With this evaluation system, the normal level of "dual
gender specific cytokines" in all “dual gender biomarkers”,
is an index for an healthy state because it is an indicator of
the ability to maintain physiological homeostasis (Figure 5).
Level variation of "dual gender specific cytokines" (for
example IFNγ-IL10, IL6-IL and IFNγ-IL4 in men) in aFigure 6 The normal level of "dual gender specific cytokines" in all “d
it is an indicator of the ability to maintain physiological homeostasis.
IL10, IL6-IL4 and IFNγ-IL4 in men) in a direction that agrees with the positiv
is an index for a transient inflammation, because it is still an indicator of im
cytokines" in a direction that does not agree (in this case negative) with th
chronic inflammation, because it is an indicator of loss of homeostatic abilidirection that agrees with the positive or negative sign of
their healthy relationship (in this case positive), it is an
index for a transient inflammation, because it is still
an indicator of immune system homeostasis; the level
variation of "dual gender specific cytokines" in a direc-
tion that does not agree (in this case negative) with
the positive or negative sign of their healthy relation-
ship, it is index for a chronic inflammation, because it
is an indicator of loss of homeostatic ability (Figure 6).
These new “panel” of biomarkers, predictive for a) the
inflammation state and b) the specific type of disease
involved, may lead to reduces diseases incidence rate
and to distinguish clinical subtypes of a single disease to
better tailor both, potential prevention strategies and/or
early intervention protocols for chronic degenerative
diseases, maintaining an acceptable quality of life.
Further study will validate or refute this new hypoth-
esis. Operative proposals for the heath care systems are
now needed to verify potential benefits in predictive
medicine.ual gender biomarkers”, is an index for an healthy state because
Level variation of "dual gender specific cytokines" (for example IFNγ-
e or negative sign of their healthy relationship (in this case positive), it
mune system homeostasis. Level variation of "dual gender specific
e positive or negative sign of their healthy relationship, it is index for a
ty.
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